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The cBio Cancer Genomics Portal: An Open Platform for 
exploring Multidimensional Cancer Genomics Data
Ethan Cerami1, Jianjiong Gao1, Ugur Dogrusoz3, Benjamin E. Gross1, Selcuk Onur Sumer3, Bülent Arman 
Aksoy1,2, Anders Jacobsen1, Caitlin J. Byrne1, Michael L. Heuer, Erik Larsson1, Yevgeniy Antipin1, Boris Reva1, 
Arthur P. Goldberg1, Chris Sander1, and Nikolaus Schultz1
summary: The cBio Cancer Genomics Portal (http://cbioportal.org) is an open-access resource for interactive 
exploration of multidimensional cancer genomics data sets, currently providing access to data from more 
than 5,000 tumor samples from 20 cancer studies. The cBio Cancer Genomics Portal significantly lowers the 
barriers between complex genomic data and cancer researchers who want rapid, intuitive, and high-quality 
access to molecular profiles and clinical attributes from large-scale cancer genomics projects and empowers 
researchers to translate these rich data sets into biologic insights and clinical applications. Cancer Discov; 2(5); 
401–4. ©2012 AACR.
With the rapidly declining cost of next-generation sequenc-
ing, and major national and international efforts, including The 
Cancer Genome Atlas (TCGA) and the International Cancer 
Genome Consortium (ICGC) (1), the field of cancer genom-
ics continues to advance at an extraordinarily rapid pace. Data 
generated by these projects are, however, not easily or directly 
available to the cancer research community, hindering the 
translation of genomic data into new biologic insights, drugs, 
and clinical trials. The cBio Cancer Genomics Portal (http://
cbioportal.org), developed at Memorial Sloan-Kettering 
Cancer Center (MSKCC), was specifically designed to address 
the unique data integration issues posed by large-scale cancer 
genomics projects and to make the raw data generated by large-
scale cancer genomic projects more easily and directly available 
to the entire cancer research community (Fig. 1A).
The cBio portal currently contains 5 published data sets 
(2–5) and 15 provisional TCGA data sets. Provisional TCGA 
data sets are updated monthly, based on the latest TCGA 
production runs, and the portal will be continually updated 
as new TCGA cancer types are added. Published data sets 
include mutation data, but provisional data sets currently 
do not. As each cancer type within TCGA is finalized and so-
matic mutations are validated, mutation data will be released 
and added to the portal. In addition to mutation data, the 
portal includes copy number alterations, microarray-based 
and RNA sequencing–based mRNA expression changes, DNA 
methylation values, and protein and phosphoprotein levels.
Each data type is stored at the gene level and is then com-
bined with available deidentified clinical data such as overall 
survival and disease-free survival intervals. The data are then 
organized as a function of patient and gene, and the portal’s 
fundamental abstraction is the concept of altered genes; spe-
cifically, we classify a gene as altered in a specific patient if it 
is mutated, homozygously deleted, amplified, or its relative 
mRNA expression is less than or greater than a user-defined 
threshold. The notion of altered genes is a powerful sim-
plifying concept that enables users to analyze complex data 
sets and to develop biologic hypotheses regarding recurrently 
 altered gene sets and biologic pathways.
A key feature of the cBio portal is ease of use. All features 
of the portal are therefore available through a streamlined 
4-step web interface. Specifically, users are guided to select: 1) 
a cancer study of interest, for example, TCGA Glioblastoma 
Multiforme (GBM); 2) one or more genomic profiles, for ex-
ample, mutations and copy number alterations; 3) a patient 
case set, for example, all “complete” TCGA patients with 
GBM with mutation, copy number, and mRNA data; and 
4) a gene set of interest: users can enter HUGO gene sym-
bols, gene aliases, or Entrez Gene IDs and can enter arbitrary 
gene sets or pathways of interest. Users also have the option 
to automatically compute mutual exclusivity and co-occur-
rence between all pairs of genes. Finally, users have the option 
of performing cross-cancer queries, a simpler 2-step query, 
which requires only that users select “All Cancer Studies” and 
enter a gene set of interest.
For example, to visualize genomic alterations in the 
 retinoblastoma (RB) pathway in the TCGA GBM data, one 
selects options 1 to 3 as described previously and in step 4 
enters: RB1, CDK4, and CDKN2A. Based on the user input, 
the portal automatically generates a series of reports, each 
in a separate tab. The first of these reports summarizes ge-
nomic data across all patients through a concise graphical 
summary called an OncoPrint. In this graphical summary, 
individual genes are represented as rows, individual cases 
or patients are represented as columns, and glyphs and/
or color-coding is used to compactly summarize distinct 
genomic alterations, including somatic mutations, copy 
number alterations, and mRNA expression. OncoPrints can 
be extremely useful for visualizing gene set and pathway 
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Other reports, each available within a separate tab, in-
clude Network Analysis, Correlation Plots, Survival Analysis, 
Mutation Details, Event Map, Data Download, and 
Bookmark/E-mail. From these additional reports, we can, for 
example, observe that many RB1 mutations may have strong 
functional consequences (Fig. 1C, Mutation Details), as pre-
dicted by MutationAssessor.org (6). We can further assess that 
alterations across a set of cases and for visually identifying 
trends such as trends in mutual exclusivity or co-occurrence 
between gene pairs within a gene set. For example, the RB 
OncoPrint (Fig. 1B) shows that alterations of genes within 
the RB pathway tend to be mutually exclusive. Statistical 
tests for co-occurrence/mutual exclusivity are also available 
in a separate tab.
Figure 1. The cBio Cancer Genomics Portal. A, the cBio Cancer Genomics Portal is an open platform for interactively exploring multidimensional 
cancer genomics data sets in the context of clinical data and biologic pathways. B, OncoPrint of RB pathway alterations in GBM. Genomic 
alterations of different members in the RB pathway are mutually exclusive. The OncoPrint provides an overview of genomic alterations (legend) in 
particular genes (rows) affecting particular individual samples (columns). C, mutation details for RB1. The predicted functional impact of the RB1 
missense mutations in GBM can be assessed through Mutation Assessor. This includes a predicted functional impact score, a multiple sequence 
alignment of different family members, and a 3-dimensional structure view, when available. D, correlation plot for CDK4. GBM samples with CDK4 
amplification have markedly increased CDK4 mRNA expression. e, survival analysis. GBM cases with an RB pathway alteration have worse overall 
survival than cases without an RB pathway alteration. F, network view of the BRCA1/BRCA2 neighborhood in serous ovarian cancer. BRCA1 and 
BRCA2 are seed genes (indicated with thick border), and all other genes are automatically identified as altered in ovarian cancer. Multidimensional 
genomic details are shown for BRCA2 and C11orf30/EMSY. Darker red indicates increased frequency of alteration (defined by mutation, copy 
number amplification, or homozygous deletion) in ovarian cancer. G, distribution of BRCA1 mutations in ovarian cancer across protein domains. 
The 2 hot spots (p.E23fs and p.Q1756fs) represent the common founder mutations 185delAG and 5382insC frequently observed in BRCA1.
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CDK4 mRNA expression is elevated in amplified cases (Fig. 
1D, Plots Tab) and that cases with an RB pathway alteration 
have worse overall survival than cases without an RB pathway 
alteration (P = 0.0513, log-rank test; Fig. 1E, Survival Tab). 
Users can also click the Event Map or Data Download reports 
to copy and paste event information into an external spread-
sheet application or click the Bookmark/E-mail tab to share 
their results with collaborators. Users can also visualize copy 
number details by choosing to launch a web start version of 
the Integrative Genomics Viewer [IGV (7)].
The network tab provides interactive analysis and visual-
ization of networks altered in the chosen cancer study. The 
network consists of pathways and interactions derived from 
the open-source Pathway Commons Project (8). By default, 
the network of interest contains all neighbors of all seed 
genes specified by the user. If more than 50 neighbor nodes 
exist in the network, all genes are ranked by the frequency of 
genomic alteration within the specified cancer study and less 
frequently altered genes are automatically pruned from the 
network. By default, the portal also automatically overlays 
multidimensional genomic data onto each node, highlight-
ing the frequency of alteration by mutation and copy number 
alteration (and optionally mRNA up-/downregulation). This 
provides an effective means of managing network complexity 
while automatically highlighting those genes most directly 
relevant to the cancer type in question. One can also down-
load the full, nonpruned network for more complete visual-
ization and analysis.
For example, we used the portal to identify genomic al-
terations in the homologous recombination (HR) DNA re-
pair pathway in serous ovarian cancer. BRCA1 and BRCA2 
are known to be involved in the HR pathway, but additional 
defects may also abrogate HR functionality and lead to po-
tential sensitivity to PARP inhibitors (9). To identify poten-
tial HR defects in ovarian cancer, we used BRCA1 and BRCA2 
as seed nodes for the network view and explored the result-
ing altered network of interest (Fig. 1F). By this means, we 
quickly identified alterations in C11orf30/EMSY (6% by am-
plification, 1.6% by mutation), a known interactor of BRCA2, 
as a possible alternate means for abrogating HR functionality 
(9). Users can also filter the network by alteration frequency, 
highlight all neighbors of a selected gene, hide specific nodes, 
crop to a selected set of nodes, or search the network by gene 
symbol. For example, we used the gene search filter to iden-
tify all altered Fanconi Anemia genes [another family of genes 
involved in the HR pathway (9)] and identified low frequency 
alterations in FANCA (altered in 3.5% of patients) and FANCE 
(2.8% of patients).
The portal also supports visualization of mutations in 
the context of protein domains from Pfam (10). For ex-
ample, the most common mutations in BRCA1 are germline 
frameshift mutations in codons 23 and 1756, also known 
as the 185delAG and 5382insC founder mutations, respec-
tively [11 (Fig. 1G)].
Protein and phosphoprotein data integration and analy-
sis are also available within the cBio portal. For example, 
large-scale proteomics data from reverse-phase protein array 
(12) are available for ovarian cancer, GBM, and colorectal 
cancer. The portal generates scatterplots of protein level ver-
sus mRNA expression for query genes if both data types are 
available. The portal also correlates genomic events of query 
genes with protein and phosphoprotein level changes. After 
a query from a user, all samples are separated into 2 groups: 
those that are altered in the query genes and those that 
are not. For each available protein or phosphoprotein level, 
a 2-sample Student t test for difference between the 2 groups 
of samples is performed and a P value is calculated. The user 
is then provided with a list of proteins or phosphoproteins 
that have significant changes between altered and unal-
tered samples. For example, using the portal, you can find 
that PTEN deletion in ovarian cancer is, as expected, tightly 
 correlated with elevated phosphorylation of AKT (pS473 and 
pT308).
As an advanced feature, researchers can use the Onco 
Query Language to define specific types of genetic altera-
tions for study within the cBio portal. For example, a user 
can specify that they only wish to see homozygous dele-
tions and mutations, but not amplifications for PTEN, and 
this setting will be reflected in the automatically generated 
OncoPrint and other plot and download features of the por-
tal. The cBio portal also provides a complete web service 
interface and libraries for MATLAB and the R statistical 
package. Finally, the portal source code is freely available 
under the GNU Lesser GPL open-source license and hosted 
on Google code (http://code.google.com/p/cbio-cancer- 
genomics-portal/). Research groups wishing to install local 
instances of the portal to analyze their own data sets can 
do so by following the installation guide or use one of the 
prebuilt Amazon Machine Images but may require the assis-
tance of system administrators.
In summary, the cBio portal facilitates access to cancer 
genomic data sets for the entire biomedical community. It 
provides a simple yet flexible interface to integrated data sets, 
intuitive visualization options, and a programmatic web in-
terface, all of which can aid researchers in translating cancer 
genomic data into biologic insights and potential clinical ap-
plications. By integrating multiple genomic data types and 
lowering the barrier to access, the portal enables researchers 
to more easily mine genomic data, test hypotheses regard-
ing genetic alterations in cancer, and place genomic data 
in the context of prior biologic knowledge. The cBio portal 
complements existing tools, including the TCGA and ICGC 
data portals (13), the IGV (7), the UCSC Cancer Genomics 
Browser (14), and IntOGen (15) by offering a unique focus 
on analyzing discrete genomic events across integrated data 
types, ease of use, support for exploratory data analysis, and 
interactive network analysis.
We anticipate several future directions for the portal. First, 
we intend to add many additional cancer studies, mostly 
from the TCGA and ICGC. Based on the current production 
schedules, we anticipate that the public portal will grow by 
at least 5 additional tumor types and more than 1,000 tu-
mor samples by the third quarter of 2012. Second, we plan 
to add several new features, including complete support for 
miRNA expression, interactive OncoPrints, batch download 
of complete data sets, summary reports for cancer studies 
(e.g., frequently mutated genes), and further extensions to 
the cross-tumor query analysis.
User support for the cBio Cancer Genomics Portal is avail-
able via e-mail at: cbioportal@googlegroups.com.
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CORRECTION
 Correction: The cBio Cancer 
Genomics Portal: An Open 
Platform for Exploring 
Multidimensional Cancer 
Genomics Data 
 In this article ( Cancer Discovery 2012;2:401–4), which was published in the May 2012 issue of 
 Cancer Discovery ( 1 ), the following was inadvertently omitted from the Grant Support statement: 
“Funding for the integration with the Integrative Genomics Viewer (IGV) is provided by the Starr 
Cancer Consortium (I5-A500).”  The authors regret this error. 
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